We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Empagliflozin (Jardiance) — SGLT2 inhibitor
An SGLT2-inhibitor diabetes drug (Jardiance) with the strongest human outcome evidence of its class — it cuts cardiovascular death, heart-failure hospitalization, and kidney-disease progression even in non-diabetics. The most widely used SGLT2 for off-label 'longevity,' though longevity itself is unproven (the lifespan data are for sibling canagliflozin in mice). A prescription drug, not a supplement.
Prescription medication — not a dietary supplement
Empagliflozin is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Empagliflozin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2012–2026 with a typical study size of 172 participants.
Based on 594 studies · 154 meta-analyses · 409 RCTs · 41,396 total participants
Confidence
High confidenceBy outcome
Empagliflozin has the strongest human outcome evidence of the SGLT2 class — reduced cardiovascular death, heart-failure hospitalization, and kidney-disease progression including in non-diabetics — but those are cardiorenal outcomes, not a demonstrated lifespan extension (the class lifespan data are for canagliflozin in mice), and it carries class risks, so the longevity use stays emerging.
783 rigorous studies
442 randomized trials · 293 meta-analyses · 48 systematic reviews
Our evidence rating for Empagliflozin is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
174 trials ongoing or recruiting · 327 completed on ClinicalTrials.gov
125 of the completed trials have posted results
Registered trials show research momentum for Empagliflozin, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Aug 2026
Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor — a 'gliflozin' — that lowers blood glucose by blocking renal glucose reabsorption, excreting glucose (and calories) in the urine, and shifting metabolism toward fat/ketone utilization.
Among the SGLT2 inhibitors it has the deepest and most consistent human outcome evidence, which is why it is the SGLT2 most commonly discussed and used off-label as a geroprotector.
The landmark EMPA-REG OUTCOME trial showed empagliflozin reduced cardiovascular death and all-cause mortality in type-2 diabetics at high cardiovascular risk; the EMPEROR trials extended heart-failure benefit to patients with both reduced and preserved ejection fraction (including many non-diabetics); and EMPA-KIDNEY showed it slows progression of chronic kidney disease across a broad population.
These are large, robust, mortality- and organ-protective outcomes — unusual for a 'metabolic' drug.
The honest distinction for this collection: those proven benefits are cardiovascular, heart-failure, and renal, not a demonstrated lifespan or healthspan extension; the only direct geroscience lifespan data in the class are for the sibling canagliflozin in male mice.
The class risks are shared: genital mycotic infections, volume depletion, and a rare but serious euglycemic diabetic ketoacidosis (higher risk with fasting/low-carb). Empagliflozin is a prescription drug; using it off-label for longevity is increasingly common, but the longevity benefit specifically is unproven.
The score reflects genuinely strong human cardiovascular/renal/heart-failure outcomes plus a class geroscience rationale, against unproven human longevity and real risks.
Blocks renal SGLT2 so glucose (and calories) are excreted in urine, lowering glucose independent of insulin.
Reduced preload, improved cardiac energetics, and lower intraglomerular pressure underlie the heart-failure and kidney benefits — largely independent of glucose lowering.
Urinary calorie loss and a shift toward fat/ketone utilization drive modest weight/BP reduction and the proposed geroprotective metabolic effects.
How Empagliflozin works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Caution — combined with carb restriction, SGLT2 inhibition can raise ketoacidosis risk.
Monitor for volume depletion and falls.
May be a poor fit — glucosuria promotes recurrence.
Additive volume depletion / hypotension.
Increased hypoglycemia risk (and ketoacidosis if insulin is reduced too much).
Tip: Glucosuria promotes yeast; hygiene and prompt treatment help.
Tip: Stay hydrated; caution with diuretics or in the elderly.
Tip: Can occur at near-normal glucose; seek care for nausea/malaise/rapid breathing, especially when fasting or ill.
Empagliflozin has an evidence score of 4.5/10 — emerging evidence based on 380 indexed studies. An SGLT2-inhibitor diabetes drug (Jardiance) with the strongest human outcome evidence of its class — it cuts cardiovascular death, heart-failure hospitalization, and kidney-disease progression even in non-diabetics. The most widely used SGLT2 for off-label 'longevity,' though longevity itself is unproven (the lifespan data are for sibling canagliflozin in mice). A prescription drug, not a supplement. Representative study: PMID 26378978.
The commonly studied dose of Empagliflozin is Off-label use mirrors approved dosing (10–25 mg once daily in the morning) under a clinician. A prescription drug; not an approved longevity regimen.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Empagliflozin is in the morning. It can be taken on an empty stomach. Once daily in the morning, with or without food; ensure hydration and genital hygiene to limit infection risk.
Empagliflozin should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are genital yeast infection, volume depletion / dizziness, euglycemic diabetic ketoacidosis. Use caution if any of these apply to you: Type 1 diabetes (ketoacidosis risk); Severe renal impairment per label / dialysis; History of recurrent diabetic ketoacidosis.
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism — comparable to metformin in some trials.
Orlistat
Mostly mechanism / observationalA gastrointestinal lipase inhibitor that blocks roughly 30% of dietary fat from being absorbed. It is the only weight-loss drug sold both on prescription (Xenical 120 mg) and over the counter (Alli 60 mg). The evidence base is large and old: across 16 long-term randomised trials it produces about 2.9 kg more weight loss than placebo, and in the 4-year XENDOS trial it cut new type 2 diabetes from 9.0% to 6.2%, though exploratory analysis found the effect was detectable ONLY in the ~21% of participants who already had impaired glucose tolerance. The trade-off is that the unabsorbed fat leaves in the stool — oily spotting, faecal urgency and steatorrhoea — and it measurably impairs fat-soluble vitamin absorption, which is what drives its real drug interactions (warfarin, levothyroxine, ciclosporin). Modest, unglamorous, and hard to stay on.
Canagliflozin
Mostly mechanism / observationalAn SGLT2-inhibitor diabetes drug (Invokana) that lowers glucose by excreting it in urine. It extended lifespan in male mice in the NIA aging program, and the SGLT2 class has strong proven cardiovascular, kidney, and heart-failure benefits in humans. Longevity benefit itself is unproven; carries genital-infection and (rarely) ketoacidosis risks. Prescription drug, not a supplement.
Dapagliflozin
Mostly mechanism / observationalAn SGLT2-inhibitor diabetes drug (Farxiga/Forxiga) with broad, robust human outcome evidence — it cuts heart-failure hospitalization and cardiovascular death across the ejection-fraction spectrum and slows kidney-disease progression, including in non-diabetics. The sibling of empagliflozin, used off-label for 'longevity,' though longevity itself is unproven (the lifespan data are for sibling canagliflozin in mice). A prescription drug, not a supplement.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 594 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research